Condition: Colon Cancer · Rectal Cancer · Sponsor: Rutgers, The State University of New Jersey
This study is to evaluate the disease control rate and time to progression of the sequential combination of oxaliplatin with an alternative anti-metabolite Trifluridine/tipiracil hydrochloride mixture, TAS-102,(TAS-OX) as well as irinotecan in combination with TAS-102 oxaliplatin(TAS-OX) + Bevacizumab in late-line metastatic colorectal cancer (mCRC)
This description comes directly from the study's public registry record.
Howard S. Hochster, MD · 732-253-5618 · howard.hochster@rutgers.edu
Always discuss trial participation with your own doctor first.
| Trinitas Hospital and Comprehensive Cancer Center | Elizabeth, New Jersey, United States | Recruiting |
| RWJBarnabas Health Jersey City Medical Center | Jersey City, New Jersey, United States | Recruiting |
| RWJBarnabas Health - Monmouth Medical Center Southern Campus | Lakewood, New Jersey, United States | Recruiting |
| Cooperman Barnabas Medical Center (Saint Barnabas Medical Center) | Livingston, New Jersey, United States | Recruiting |
| RWJBarnabas Health - Monmouth Medical Center | Long Branch, New Jersey, United States | Recruiting |
| Rutgers Cancer Institute of New Jersey | New Brunswick, New Jersey, United States | Recruiting |
| RWJBarnabas Health - Robert Wood Johnson University Hospital | New Brunswick, New Jersey, United States | Recruiting |
| RWJBarnabas Health - Robert Wood Johnson University Hospital | Somerset, New Jersey, United States | Recruiting |
| RWJBarnabas Health - Community Medical Center | Toms River, New Jersey, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05806931